Background
In January 2024, bictegravir (BIC) was upgraded to an alternative antiretroviral therapy in pregnancy in the United States despite limited data. Our study aimed to examine the perinatal and early infant outcomes following BIC exposure in pregnancy in Canada.
Methods
Data was obtained from the Canadian Perinatal HIV Surveillance Program, which is a prospective cohort of infants born to women living with HIV across 23 Canadian centers. Liveborn infants from July 28, 2018 to December 31, 2023 were included in the analysis. Using univariate analyses, BIC-exposed infants were compared to infants born within the same timeframe with exposure to other integrase strand transfer inhibitors (INSTIs). To identify whether preterm births were independently associated with BIC exposure, a logistic regression analysis adjusting for relevant preterm birth risk factors.
Results
In our included cohort, 161 infants were exposed to BIC in pregnancy, and 723 infants were exposed to non-BIC INSTIs. In the BIC-exposed group, 81 (52%) had pre-conception BIC with continued use in pregnancy, 34 (22%) had pre-conception BIC with discontinuation in pregnancy, and 41 (26%) were started on BIC in pregnancy. Infants exposed to BIC were more likely to be born to mothers identified as Indigenous (38% vs. 21%; p < 0.001) and with a mode of transmission associated with intravenous drug use (28% vs. 14%; p<0.001). Infants exposed to BIC in pregnancy were more likely to be born preterm (19.4% vs 11.7%; p=0.008), and their mothers were more likely to discontinue antiretroviral therapy until delivery (1.9% vs. 0.1%; p=0.021) and in the postpartum period (5.0% vs. 2.0%; p=0.037). After adjusting for ethnicity, maternal mode of HIV transmission, and viral load at delivery, preterm birth was not associated with BIC exposure (OR: 1.47; 95% CI: 0.80-2.71; p=0.214). There were no differences in maternal HIV viral load at delivery, mode of delivery, rate of small for gestational age, rate of perinatal transmission, or rate of congenital anomalies.
Conclusions
BIC was not independently associated with adverse perinatal and early infant outcomes compared to other INSTIs in the Canadian cohort. Indigenous populations and people who use injection drugs were disproportionately exposed to off-label BIC use in pregnancy prior to guideline updates, highlighting a gap in preconception counselling in these populations.
Table or Figure
![]()